Liquet Medical’s Versus Catheter Receives FDA Clearance

December 10, 2024—Liquet Medical Inc. announced it has received FDA 510(k) clearance for its Versus catheter for the treatment of pulmonary artery blood clots.

According to Liquet Medical, the Versus device provides real-time pulmonary artery pressure measurements to optimize treatment based on individual patient responses. The new technology enables a treatment that the company calls “hemodynamics-led thrombolysis.”

In Liquet Medical’s press release, the company outlined key features of the Versus catheter which include the following: 

• The real-time pulmonary artery pressure monitoring provides physicians with live data to assess patient hemodynamics before and during therapy to optimize treatment decisions.
• The dual-tip telescoping catheter enables simultaneous treatment of both lungs with a single device, offering access-site alternatives to the physician and improving health care efficiency.
•  The flexible placement allows for a standard guidewire technique or flow-directed balloon placement.

“The Versus catheter will allow for a more datacentric approach to each individual patient suffering from blood clots in their lungs,” commented Luke Wilkins, MD, in the company’s press release. Dr. Wilkins, who is an interventional radiologist at UVA Health in Charlottesville, Virginia, added, “Hemodynamics-led thrombolysis therapy is an opportunity to potentially improve patient outcomes, and we are looking forward to studying this device.”